EGS P11 Ten year experience of treating Boerhaave syndrome: a single centre analysis


 
 
 Boerhaave syndrome is a rare condition characterised by spontaneous barogenic, transmural rupture of the oesophagus. We aimed to examine a ten-year experience of Boerhaave syndrome at our centre.
 
 
 
 Cohort analysis of Boerhaave syndrome over a ten year period (2012–2022). Univariate analysis was employed to determine risk factors associated with inferior patient survival.
 
 
 
 During the study period, 40 patients presented with oesophageal perforation, of which 21 (52.5%) were spontaneous transmural rupture. Median age of patients with Boerhaave syndrome was 51 years, in predominantly male (15, 71.4%), non-smokers (13, 61.9%). The most common site of rupture was the lower oesophagus (12, 57.1%), although the exact site of rupture was unknown in 5 (23.8%) patients. 14 (66.7%) patients were treated conservatively with antibiotics. Three (14.3%) patients underwent endoscopic oesophageal stent insertion (either alone or in combination with surgical treatment). Five (23.0%) underwent thoracoscopic washout and drain insertion and 1 (4.8%) underwent open thoracotomy washout and drain insertion. Overall 10-year survival was 80.8%. There was no association between mortality and patient age, sex, smoking status, length of stay, location of perforation, coronavirus status or mode of nutrition on univariate analysis (p>0.05 throughout). Patient age was the greatest predictor of prolonged length of stay beyond 10 days (c-statistic 0.74). Modality of surgery also had no bearing on 1- and 10-year mortality (p=0.95).
 
 
 
 Boerhaave syndrome is an uncommon condition which may be treated with an array of approaches, including non-operative measures, endoscopic and surgical intervention, depending on individual patient characteristics. The availability of multimodal treatment at a specialist oesophagogastric centre may have contributed to favourable patient outcomes. Given the rarity of Boerhaave syndrome, identification of risk factors for poor patient outcomes is difficult to determine, due to statistical underpowering.
